Study S001035

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05929066
Acronym: TRIUMPH-1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 2335
Start: 2023-07-10
Primary completion: 2026-04-06
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea
Interventions: DRUG:Retatrutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J1I-MC-GZBJ; OTHER:J1I-MC-GOA1; OTHER:J1I-MC-GSA1; OTHER:2023-503657-35-00; NIH:2023

Registered primary outcomes

Percent Change From Baseline in Body Weight [Baseline, Week 80]
Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset [Baseline, Week 80]
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score for GOA1 Subset [Baseline, Week 80]
Percent Change from Baseline in Body Weight in Participants in Extension Subset [Baseline, Week 104]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010544	Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. Jastreboff AM, The New England journal of medicine	2026	Randomized trial	PMID 42814954 DOI	cites ClinicalTrials.gov:NCT05929066; registry reference DERIVED:42814954